# CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

> **NCT03556982** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of the Chinese Academy of Military Medical Sciences** · enrollment: 10 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **BIOLOGICAL:** CART-123 cells

## Key facts

- **NCT ID:** NCT03556982
- **Lead sponsor:** The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556982, "CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03556982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*